TherapeuticsMD Inc (NASDAQ:TXMD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

A number of other equities research analysts have also issued reports on TXMD. Oppenheimer Holdings, Inc. started coverage on shares of TherapeuticsMD in a research note on Tuesday, November 22nd. They set an “outperform” rating and a $12.00 target price for the company. Jefferies Group started coverage on shares of TherapeuticsMD in a research note on Tuesday, November 22nd. They set a “buy” rating and a $18.00 target price for the company. Guggenheim reissued a “buy” rating on shares of TherapeuticsMD in a research note on Tuesday, November 29th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $10.50 target price on shares of TherapeuticsMD in a research note on Sunday, December 4th. Finally, Stifel Nicolaus lifted their price objective on shares of TherapeuticsMD from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, December 6th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $14.38.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/01/11/therapeuticsmd-inc-txmd-rating-lowered-to-sell-at-zacks-investment-research.html

Shares of TherapeuticsMD (NASDAQ:TXMD) traded down 4.17% during mid-day trading on Wednesday, hitting $5.74. The stock had a trading volume of 1,577,736 shares. The stock has a 50-day moving average price of $6.14 and a 200 day moving average price of $6.78. TherapeuticsMD has a 52 week low of $4.39 and a 52 week high of $9.29. The stock’s market cap is $1.13 billion.

COPYRIGHT VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of US & international copyright and trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/01/11/therapeuticsmd-inc-txmd-rating-lowered-to-sell-at-zacks-investment-research.html.

Several large investors have recently added to or reduced their stakes in the stock. BlackRock Group LTD raised its stake in TherapeuticsMD by 2.9% in the third quarter. BlackRock Group LTD now owns 102,236 shares of the company’s stock valued at $695,000 after buying an additional 2,861 shares during the last quarter. Rhumbline Advisers increased its position in TherapeuticsMD by 1.6% in the third quarter. Rhumbline Advisers now owns 159,694 shares of the company’s stock valued at $1,088,000 after buying an additional 2,540 shares during the last quarter. BlackRock Fund Advisors increased its position in TherapeuticsMD by 9.2% in the third quarter. BlackRock Fund Advisors now owns 5,059,418 shares of the company’s stock valued at $34,455,000 after buying an additional 426,991 shares during the last quarter. BlackRock Inc. increased its position in TherapeuticsMD by 7.1% in the third quarter. BlackRock Inc. now owns 16,303 shares of the company’s stock valued at $111,000 after buying an additional 1,080 shares during the last quarter. Finally, BlackRock Investment Management LLC increased its position in TherapeuticsMD by 1.3% in the third quarter. BlackRock Investment Management LLC now owns 569,885 shares of the company’s stock valued at $3,881,000 after buying an additional 7,579 shares during the last quarter.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.